triple acting glp 1 parkinson's disease agonist glp-1 gip glucagon clinical trial Current Insights, Advantages and Challenges of Frontiers | Mechanisms of action
Description
Miroczuk-ChodakowskaIKujawowiczKWitkowskaAM
Long-term safety data continues to emerge for newer medications like tirzepatide
This is important context that goes beyond general GLP-1 side effects
Many patients wonder if they can safely quit their weight loss medication, and the answer depends on your individual health goals, metabolic status, and the underlying factors driving your weight
And how the medication works in your body
